The development of an ophthalmic-formulated version of this drug will serve to eliminate or minimize the involvement of IL-4 and IL-13 in mediating type 2 inflammatory processes in allergic conjunctivitis. This evidence concerns the gene IL4 and atopic conjunctivitis.